NASDAQ:IPSC
Century Therapeutics Inc (IPSC) receives a Buy rating from Rodman & Renshaw
Century Therapeutics Inc’s recently made public that its Chief Scientific Officer Cowan Chad acquired Company’s shares for reported $49252.0 on ...
Century Therapeutics Inc (IPSC) receives a Buy rating from Rodman & Renshaw
Century Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Cowan Chad acquired Company’s shares for reported $49252.0 on ...
Investing in Century Therapeutics Inc (IPSC) Is Getting More Attractive
Century Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Cowan Chad acquired Company’s shares for reported $49252.0 on ...
Century Therapeutics Inc (IPSC) Becoming More Attractive for Investors
Century Therapeutics Inc’s filing revealed that its Chief Scientific Officer Cowan Chad acquired Company’s shares for reported $49252.0 on Dec ...
Investing in Century Therapeutics Inc (IPSC): What You Must Know
Century Therapeutics Inc’s recently made public that its President and CEO Pfeiffenberger Brent acquired Company’s shares for reported $30352.0 on ...
Investing in Century Therapeutics Inc (IPSC): What You Must Know
Century Therapeutics Inc’s recently made public that its President and CEO Pfeiffenberger Brent acquired Company’s shares for reported $30352.0 on ...
